New FDA Approvals: FDA Approves Besremi | Dec. 9, 2021

Nov. 12: The FDA approved PharmaEssentia Corp.’s Besremi (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera. It is the first interferon therapy that the agency has approved specifically for the condition. The drug received orphan drug designation for the indication. The recommended starting dose is 100 mcg by subcutaneous injection every two weeks. The dose can be increased by 50 mcg every two weeks up to a maximum of 500 mcg until hematological parameters are stabilized.

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured-Image_AdobeStock_438621431.jpg
January 13

Medicare Plans to Cover Aduhelm but With Certain Restrictions

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-radar-on-specialty-pharmacy-FDA-Extends-Xeljanz-Safety-Warnings-to-Other-JAK-Inhibitors.jpg
January 13

Notable 2021 Approvals Included Oncolytics, Interchangeables

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured-Image_AdobeStock_199469526.jpg
January 13

Many Melanoma Therapies Exist, but Treatment Remains Challenging

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today